(Q34400638)

1 August 2017

1 reference

title

How well tolerated are lipid-lowering drugs? (English)

1 reference

1 August 2017

B Tomlinson

1

1 reference

1 August 2017

P Chan

series ordinal

2

1 reference

1 August 2017

W Lan

series ordinal

3

1 reference

1 August 2017

1 January 2001

1 reference

1 August 2017

1 reference

1 August 2017

18

1 reference

1 August 2017

9

1 reference

1 August 2017

665-683

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-200118090-00003

1 August 2017

0 references

cites work

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Cholesterol, depression and suicide

1 reference

12 December 2020

Pathogenesis and management of lipoprotein disorders

1 reference

12 December 2020

Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions

1 reference

12 December 2020

Simvastatin-induced acute pancreatitis: two cases

1 reference

12 December 2020

Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation

1 reference

12 December 2020

Lovastatin. Warfarin interaction

1 reference

12 December 2020

Gemfibrozil-induced myopathy

1 reference

12 December 2020

Low serum cholesterol and suicide

1 reference

12 December 2020

Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors

1 reference

12 December 2020

Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin

1 reference

12 December 2020

Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses

1 reference

12 December 2020

Clinical pharmacokinetics of fibric acid derivatives (fibrates).

1 reference

12 December 2020

Acute cholestatic hepatitis during simvastatin administration

1 reference

12 December 2020

HMG-CoA reductase inhibitors for hypercholesterolemia

1 reference

12 December 2020

Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes

1 reference

12 December 2020

Effects of fluvastatin on human biliary lipids.

1 reference

12 December 2020

Rhabdomyolysis associated with simvastatin-gemfibrozil therapy.

1 reference

12 December 2020

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions

1 reference

12 December 2020

Should there be a moratorium on the use of cholesterol lowering drugs?

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors--simvastatin and pravastatin

1 reference

12 December 2020

Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease?

1 reference

12 December 2020

Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation

1 reference

12 December 2020

Subarachnoid hemorrhage, cerebral hemorrhage, and serum cholesterol concentration in men and women

1 reference

12 December 2020

A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial

1 reference

12 December 2020

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy

1 reference

12 December 2020

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

1 reference

12 December 2020

Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin

1 reference

12 December 2020

Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.

1 reference

12 December 2020

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study

1 reference

12 December 2020

HMG-CoA reductase inhibitor use in the aged. A review of clinical experience

1 reference

12 December 2020

Assessing possible hazards of reducing serum cholesterol

1 reference

12 December 2020

Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin

1 reference

12 December 2020

Pharmacokinetic and bioequivalence study of two gemfibrozil preparations

1 reference

12 December 2020

An overview of trials of cholesterol lowering and risk of stroke

1 reference

12 December 2020

Gemfibrozil-induced impotence

1 reference

12 December 2020

Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin

1 reference

12 December 2020

Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers

1 reference

12 December 2020

Fluvastatin with and without niacin for hypercholesterolemia

1 reference

12 December 2020

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

1 reference

12 December 2020

Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion

1 reference

12 December 2020

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

1 reference

12 December 2020

Cerebrovascular diseases in a fixed population of Hiroshima and Nagasaki, with special reference to relationship between type and risk factors

1 reference

12 December 2020

Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction

1 reference

12 December 2020

Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor.

1 reference

12 December 2020

The prevalence of side effects with regular and sustained-release nicotinic acid

1 reference

12 December 2020

Update of hepatotoxicity due to classes of drugs in common clinical use: non-steroidal drugs, anti-inflammatory drugs, antibiotics, antihypertensives, and cardiac and psychotropic agents

1 reference

12 December 2020

Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors

1 reference

12 December 2020

Antihyperlipidaemic agents. Drug interactions of clinical significance

1 reference

12 December 2020

Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin

1 reference

12 December 2020

The aetiology and management of erectile, ejaculatory, and fertility problems in men with diabetes mellitus

1 reference

12 December 2020

The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia.

1 reference

12 December 2020

WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators

1 reference

12 December 2020

Does lowering cholesterol cause cancer?

1 reference

12 December 2020

Association of low serum total cholesterol with major depression and suicide.

1 reference

12 December 2020

Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy

1 reference

12 December 2020

Clofibrate-induced muscular syndrome. Case report with ultrastructural findings and review of the literature.

1 reference

12 December 2020

Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety

1 reference

12 December 2020

Clinical outcomes in statin treatment trials: a meta-analysis

1 reference

12 December 2020

Are psychoactive-drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders?

1 reference

12 December 2020

Low total serum cholesterol and intracerebral hemorrhagic stroke: is the association confined to elderly men? The Kaiser Permanente Medical Care Program

1 reference

12 December 2020

Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?

1 reference

12 December 2020

Clofibrate therapy and gallstone induction

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

HMG-CoA reductase inhibitors in organ transplantation

1 reference

12 December 2020

Drug interactions with fibric acids

1 reference

12 December 2020

Long-term safety and efficacy profile of simvastatin

1 reference

12 December 2020

Pravastatin Therapy and the Risk of Stroke

1 reference

12 December 2020

Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias

1 reference

12 December 2020

Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia

1 reference

12 December 2020

Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia

1 reference

12 December 2020

Acute hepatic failure associated with the use of low-dose sustained-release niacin

1 reference

12 December 2020

Stroke subtypes among Chinese living in Hong Kong: the Shatin Stroke Registry

1 reference

12 December 2020

Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolaemia

1 reference

12 December 2020

Hepatic toxicity of unmodified and time-release preparations of niacin

1 reference

12 December 2020

Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients

1 reference

12 December 2020

Simvastatin seems unlikely to cause impotence

1 reference

12 December 2020

Carcinogenicity of lipid-lowering drugs

1 reference

12 December 2020

Serum cholesterol concentration and death from suicide in men: Paris prospective study I.

1 reference

12 December 2020

Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?

1 reference

12 December 2020

Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies

1 reference

12 December 2020

Management of lipid disorders in the elderly

1 reference

12 December 2020

The Helsinki Heart Study: an 8.5-year safety and mortality follow-up

1 reference

12 December 2020

Pharmacokinetics of fluvastatin and specific drug interactions

1 reference

12 December 2020

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up. The Lipid Research Clinics Investigators

1 reference

12 December 2020

Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program

1 reference

12 December 2020

Effects of lovastatin in humans on biliary lipid composition and secretion as a function of dosage and treatment interval.

1 reference

12 December 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

12 December 2020

Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease

1 reference

12 December 2020

Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance

1 reference

12 December 2020

Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients

1 reference

12 December 2020

Low serum cholesterol as a risk factor for hemorrhagic stroke in men: a community-based mass screening in Okinawa, Japan

1 reference

12 December 2020

Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor

1 reference

12 December 2020

Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin

1 reference

12 December 2020

HMG-CoA reductase inhibitor-induced impotence.

1 reference

12 December 2020

Low serum cholesterol concentration and serotonin metabolism in men.

1 reference

12 December 2020

Effects of lovastatin and pravastatin on sleep efficiency and sleep stages

1 reference

12 December 2020

Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro

1 reference

12 December 2020

Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia

1 reference

12 December 2020

Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study

1 reference

12 December 2020

Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia

1 reference

12 December 2020

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

12 December 2020

Clofibrate and niacin in coronary heart disease

1 reference

12 December 2020

Lovastatin-induced myopathy in a hypothyroid patient

1 reference

12 December 2020

Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study.

1 reference

12 December 2020

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

1 reference

12 December 2020

Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors

1 reference

12 December 2020

Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial.

1 reference

12 December 2020

Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients

1 reference

12 December 2020

Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study

1 reference

12 December 2020

Lipoproteins, cardiovascular disease, and death. The Framingham study

1 reference

12 December 2020

Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia

1 reference

12 December 2020

Lovastatin-associated rhabdomyolysis

1 reference

12 December 2020

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

12 December 2020

HMG CoA reductase inhibitors and quality of life

1 reference

12 December 2020

Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials

1 reference

12 December 2020

Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering

1 reference

12 December 2020

Pharmacokinetics of nicotinic acid-salicylic acid interaction

1 reference

12 December 2020

Plasma concentrations of active simvastatin acid are increased by gemfibrozil

1 reference

12 December 2020

Demonstration of an association among dietary cholesterol, central serotonergic activity, and social behavior in monkeys.

1 reference

12 December 2020

Potential interaction between warfarin and fluvastatin

1 reference

12 December 2020

Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study. Oxford Cholesterol Study Group

1 reference

12 December 2020

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

1 reference

12 December 2020

Drug interactions of lipid-altering drugs

1 reference

12 December 2020

Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial

1 reference

12 December 2020

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

1 reference

12 December 2020

A review of clinical trials comparing HMG-CoA reductase inhibitors

1 reference

12 December 2020

Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia.

1 reference

12 December 2020

Preclinical evaluation of lovastatin

1 reference

12 December 2020

Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients

1 reference

12 December 2020

Promoting effects of both dietary cholesterol and cholestyramine on pancreatic carcinogenesis initiated by N-nitrosobis(2-oxopropyl)amine in Syrian golden hamsters

1 reference

12 December 2020

Lovastatin inhibits proliferation and differentiation and causes apoptosis in lipopolysaccharide-stimulated murine B cells.

1 reference

12 December 2020

Potential warfarin-fluvastatin interaction

1 reference

12 December 2020

Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin

1 reference

12 December 2020

Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio

1 reference

12 December 2020

Hepatotoxicity of anticholesterol, cardiovascular, and endocrine drugs and hormonal agents

1 reference

12 December 2020

Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment

1 reference

12 December 2020

Rhabdomyolysis after taking atorvastatin with gemfibrozil

1 reference

12 December 2020

Low serum cholesterol and haemorrhagic stroke in men: Korea Medical Insurance Corporation Study

1 reference

12 December 2020

Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group

1 reference

12 December 2020

Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans

1 reference

12 December 2020

Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model

1 reference

12 December 2020

Hypercholesterolemia in elderly persons: resolving the treatment dilemma

1 reference

12 December 2020

Carcinogenicity of lipid-lowering drugs

1 reference

12 December 2020

Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin

1 reference

12 December 2020

Low serum cholesterol and the risk of cerebral haemorrhage

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Gemfibrozil-induced impotence

1 reference

12 December 2020

Serum cholesterol and cancer risk: an epidemiologic perspective

1 reference

12 December 2020

Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias

1 reference

12 December 2020

Adverse effects of hypolipidaemic drugs.

1 reference

12 December 2020

Comment: HMG-CoA reductase inhibitor-induced impotence

1 reference

12 December 2020

Gemfibrozil-induced impotence

1 reference

12 December 2020

In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase

1 reference

12 December 2020

Fluvastatin Long-Term Extension Trial (FLUENT): summary of efficacy and safety.

1 reference

12 December 2020

Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine

1 reference

12 December 2020

A new case of simvastatin-induced acute pancreatitis

1 reference

12 December 2020

Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia

1 reference

12 December 2020

Lovastatin-induced hepatitis

1 reference

12 December 2020

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

1 reference

12 December 2020

Cholestatic jaundice associated with lovastatin (Mevacor) therapy

1 reference

12 December 2020

Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia

1 reference

12 December 2020

Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors

1 reference

12 December 2020

Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment.

1 reference

12 December 2020

Cholesterol reduction yields clinical benefit. A new look at old data

1 reference

12 December 2020

Incidence of cancer in men on a diet high in polyunsaturated fat.

1 reference

12 December 2020

Carcinogenicity of lipid-lowering drugs

1 reference

12 December 2020

Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)

1 reference

12 December 2020

Gemfibrozil-lovastatin-associated myalgia

1 reference

12 December 2020

Efficacy and long-term adverse effect pattern of lovastatin

1 reference

12 December 2020

Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.

1 reference

12 December 2020

Reductase inhibitor monotherapy and stroke prevention

1 reference

12 December 2020

Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects

1 reference

12 December 2020

Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin

1 reference

12 December 2020

Hepatitis and hematemesis complicating nicotinic acid use.

1 reference

12 December 2020

The paradox of high risk of stroke in populations with low risk of coronary heart disease

1 reference

12 December 2020

10.2165/00002512-200118090-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

0 references

1 reference